Galectin Therapeutics (GALT) Operating Expenses (2010 - 2026)

Galectin Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 48.37% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $16.3 million (down 60.02% YoY), while the FY2025 annual figure was $20.1 million, down 52.67% from the prior year.
• Operating Expenses was $4.1 million for Q1 2026 at Galectin Therapeutics, up from $3.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $12.4 million in Q4 2024 to a low of $3.4 million in Q4 2025.
• Historically, Operating Expenses has averaged $8.4 million across 5 years, with a median of $9.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 57.27% in 2022, then slumped 72.92% in 2025.
• A 5-year view of Operating Expenses shows it stood at $10.6 million in 2022, then slipped by 10.08% to $9.6 million in 2023, then grew by 29.99% to $12.4 million in 2024, then plunged by 72.92% to $3.4 million in 2025, then climbed by 21.16% to $4.1 million in 2026.
• The last three Operating Expenses figures came in at $4.1 million (Q1 2026), $3.4 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.